ID: ALA3526983

Max Phase: Preclinical

Molecular Formula: C8H12N4O7S

Molecular Weight: 308.27

Molecule Type: Small molecule

Representations

Canonical SMILES:  N[C@@H](CSCC(=O)N1CC([N+](=O)[O-])([N+](=O)[O-])C1)C(=O)O

Standard InChI:  InChI=1S/C8H12N4O7S/c9-5(7(14)15)1-20-2-6(13)10-3-8(4-10,11(16)17)12(18)19/h5H,1-4,9H2,(H,14,15)/t5-/m0/s1

Standard InChI Key:  SKPHVUHPUBXVOO-YFKPBYRVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 308.27

Molecular Weight (Monoisotopic): 308.0427

AlogP: -1.78

#Rotatable Bonds: 7

Polar Surface Area: 169.91

Molecular Species: ZWITTERION

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 11

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 1.66

CX Basic pKa: 8.83

CX LogP: -3.50

CX LogD: -3.51

Aromatic Rings: 0

Heavy Atoms: 20

QED Weighted: 0.31

Np Likeness Score: -0.35

References

1. Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, Fitch WL..  (2012)  Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.,  40  (9): [PMID:22699395] [10.1124/dmd.112.046755]

2. Oronsky B, Guo X, Wang X, Cabrales P, Sher D, Cannizzo L, Wardle B, Abrouk N, Lybeck M, Caroen S, Oronsky A, Reid TR..  (2021)  Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.,  64  (11.0): [PMID:34043360] [10.1021/acs.jmedchem.1c00599]

Source

Source(1):

• Scientific Literature